Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Dr. Darlene McCord Research
CORALVILLE, Iowa, Dec. 11, 2013 /PRNewswire/ -- McCord Research, Inc., founded by the renown biochemist, Darlene McCord, Ph.D., FAPWCA, has submitted a new patent application entitled "Hydroxytyrosol and Oleuropein Compositions For Induction of DNA Damage, Cell Death and Inhibition of LSD1", based on the exciting discovery of the ability of two phytochemicals found in olives to inhibit a molecule expressed in various cancers. The two phytochemicals, hydroxytyrosol and oleuropein, were discovered to inhibit cancer cells and inhibit the activity of lysine specific demethylase 1 (LSD1), an enzyme shown to have increased expression in multiple cancer types.
These findings as well as wound therapy-related findings described in the patent, attributed to the olive phytochemicals, that include improvement of normal cell viability, enhancement of normal angiogenesis, and treatment or prevention of high glucose or chemotherapy-induced cell dysfunction, were discovered in the leading research laboratory of Thomas C. Karagiannis at Baker IDI in Melbourne Australia.
Dr. McCord and McCord Research, Inc. has been supporting cutting-edge research such as the research described in this latest patent application for several years. She has a long-standing tradition of promoting research involving the amazing antioxidant, anti-cancer, and wound healing properties of hydroxytyrosol and oleuropein. Dr. McCord has utilized these discoveries and other research discoveries as an inventor to help her formulate her very successful skin and wound care products with Olivamine®, and her new, exciting skin and wound care product line, Viniferamine™.
For Further Information:
Darlene McCord, Ph.D., CEO, CSO
McCord Research/Pinnaclife, Inc.
©2012 PR Newswire. All Rights Reserved.